Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1990 Jun;34(6):1118–1122. doi: 10.1128/aac.34.6.1118

Safety, tolerance, and pharmacokinetic evaluation of cefepime after administration of single intravenous doses.

R H Barbhaiya 1, S T Forgue 1, C R Gleason 1, C A Knupp 1, K A Pittman 1, D J Weidler 1, R R Martin 1
PMCID: PMC171768  PMID: 2203303

Abstract

In this double-blind, single-dose phase I study, the safety and tolerance of cefepime were assessed in 24 healthy male subjects, with ceftazidime as the control drug. Four subjects in each of the six dose groups (62.5, 125, 250, 500, 1,000, or 2,000 mg as a 30-min intravenous infusion) received each antibiotic, according to a crossover design, with a 2-day washout period between treatments. Blood and urine samples were obtained to characterize the pharmacokinetics of cefepime. Plasma and urine samples were assayed for intact cefepime. Samples containing ceftazidime were discarded. The adverse effects observed in the study were mild and infrequent, with prompt recovery from adverse experiences and abnormal laboratory values. The cefepime pharmacokinetic parameters for the therapeutically significant doses of 250 to 2,000 mg appeared to be proportional to dose and similar to literature values for ceftazidime. The elimination half-life of about 2 h was independent of the dose. Urinary recovery of intact cefepime was invariant with respect to dose; an overall mean value of 82% of dose was obtained for the four highest levels. Mean renal clearance was 105 ml/min and suggestive of glomerular filtration as the primary excretion mechanism. In normal humans, the safety and pharmacokinetic profiles of cefepime are very similar to those of ceftazidime.

Full text

PDF
1122

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Badian M., Malerczyk V., Collins J. D., Dixon G. T., Verho M., Eckert H. G. Safety, tolerance and pharmacokinetics of 2.0 g cefpirome (HR 810) after single and multiple dosing. Chemotherapy. 1988;34(5):367–373. doi: 10.1159/000238594. [DOI] [PubMed] [Google Scholar]
  2. Barbhaiya R. H., Forgue S. T., Shyu W. C., Papp E. A., Pittman K. A. High-pressure liquid chromatographic analysis of BMY-28142 in plasma and urine. Antimicrob Agents Chemother. 1987 Jan;31(1):55–59. doi: 10.1128/aac.31.1.55. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bergan T. Pharmacokinetics of beta-lactam antibiotics. Scand J Infect Dis Suppl. 1984;42:83–98. [PubMed] [Google Scholar]
  4. Clarke A. M., Zemcov S. J., Wright J. M. HR 810 and BMY-28142, two new cephalosporins with broad-spectrum activity: an in-vitro comparison with other beta-lactam antibiotics. J Antimicrob Chemother. 1985 Mar;15(3):305–310. doi: 10.1093/jac/15.3.305. [DOI] [PubMed] [Google Scholar]
  5. Drusano G. L. Role of pharmacokinetics in the outcome of infections. Antimicrob Agents Chemother. 1988 Mar;32(3):289–297. doi: 10.1128/aac.32.3.289. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Forgue S. T., Shyu W. C., Gleason C. R., Pittman K. A., Barbhaiya R. H. Pharmacokinetics of the novel cephalosporin cefepime (BMY-28142) in rats and monkeys. Antimicrob Agents Chemother. 1987 May;31(5):799–804. doi: 10.1128/aac.31.5.799. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Kemmerich B., Warns H., Lode H., Borner K., Koeppe P., Knothe H. Multiple-dose pharmacokinetics of ceftazidime and its influence on fecal flora. Antimicrob Agents Chemother. 1983 Sep;24(3):333–338. doi: 10.1128/aac.24.3.333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Kessler R. E., Bies M., Buck R. E., Chisholm D. R., Pursiano T. A., Tsai Y. H., Misiek M., Price K. E., Leitner F. Comparison of a new cephalosporin, BMY 28142, with other broad-spectrum beta-lactam antibiotics. Antimicrob Agents Chemother. 1985 Feb;27(2):207–216. doi: 10.1128/aac.27.2.207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Maass L., Malerczyk V., Verho M. Pharmacokinetics of cefpirome (HR 810), a new cephalosporin derivative administered intramuscularly and intravenously to healthy volunteers. Infection. 1987 May-Jun;15(3):207–210. doi: 10.1007/BF01646052. [DOI] [PubMed] [Google Scholar]
  10. Neu H. C., Srinivasan S. Pharmacology of ceftizoxime compared with that of cefamandole. Antimicrob Agents Chemother. 1981 Sep;20(3):366–369. doi: 10.1128/aac.20.3.366. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Odenholt-Tornqvist I. Pharmacodynamics of beta-lactam antibiotics. Studies on the paradoxical and postantibiotic effects in vitro and in an animal model. Scand J Infect Dis Suppl. 1989;58:1–55. doi: 10.3109/inf.1988.20.suppl-58.01. [DOI] [PubMed] [Google Scholar]
  12. Patel I. H., Chen S., Parsonnet M., Hackman M. R., Brooks M. A., Konikoff J., Kaplan S. A. Pharmacokinetics of ceftriaxone in humans. Antimicrob Agents Chemother. 1981 Nov;20(5):634–641. doi: 10.1128/aac.20.5.634. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Phelps D. J., Carlton D. D., Farrell C. A., Kessler R. E. Affinity of cephalosporins for beta-lactamases as a factor in antibacterial efficacy. Antimicrob Agents Chemother. 1986 May;29(5):845–848. doi: 10.1128/aac.29.5.845. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Richards D. M., Brogden R. N. Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1985 Feb;29(2):105–161. doi: 10.2165/00003495-198529020-00002. [DOI] [PubMed] [Google Scholar]
  15. Tsuji A., Maniatis A., Bertram M. A., Young L. S. In vitro activity of BMY-28142 in comparison with those of other beta-lactam antimicrobial agents. Antimicrob Agents Chemother. 1985 Apr;27(4):515–519. doi: 10.1128/aac.27.4.515. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Täuber M. G., Hackbarth C. J., Scott K. G., Rusnak M. G., Sande M. A. New cephalosporins cefotaxime, cefpimizole, BMY 28142, and HR 810 in experimental pneumococcal meningitis in rabbits. Antimicrob Agents Chemother. 1985 Mar;27(3):340–342. doi: 10.1128/aac.27.3.340. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES